Veitch, Zachary http://orcid.org/0000-0002-3223-5045
Ribnikar, Domen
Tilley, Derek
Tang, Patricia A.
King, Karen
Bedard, Philippe L.
Lupichuk, Sasha
Cescon, David W. http://orcid.org/0000-0002-1080-0998
Article History
Received: 22 October 2021
Revised: 27 November 2021
Accepted: 10 December 2021
First Online: 20 December 2021
Ethics approval and consent to participate
: This study was approved by the Princess Margaret Cancer Centre Research Ethics Board (NCT03740503) and the Health and Research Ethics Board of Alberta (Cancer Committee).
: Not applicable.
: ZWV has received honoraria from Pfizer, Exact Sciences, Knight Pharmaceuticals, and Novartis. DWC reports consultancy and advisory fees from AstraZeneca, Exact Sciences, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche; research funding to their institution from GlaxoSmithKline, Inivata, Merck, Pfizer and Roche; is a member of a trial steering committee for Merck; and holds a patent (US62/675,228) for methods of treating cancers characterised by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. PLB has received research funding from Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, SERVIER, GlaxoSmithKline, Novartis, SignalChem, PTC Therapeutics, Nektar, Merck, Seattle Genetics, Mersana, Immunomedics, Eli-Lilly, Zymeworks, and VelosBio. Uncompensated advisory for Lilly, Seagen, Merck, Genentech/Roche, Bristol-Myers Squibb, and Gilead. PAT has honoraria from Teva, Eisai, Pfizer, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca and Roche. No conflicts of interest: The following authors have declared no conflicts of interest: DR, DT, KK and SL.